
  
    
      
        Background_NNP
        SLC_NNP /_NN CCL_NNP 21_CD ,_, normally_RB expressed_VBD in_IN high_JJ endothelial_NN
        venules_NNS and_CC in_IN T_NN cell_NN zones_NNS of_IN spleen_NN and_CC lymph_NN nodes_NNS ,_,
        strongly_RB attracts_VBZ T_NN cells_NNS and_CC dendritic_JJ cells_NNS (_( DC_NNP )_) [_NN 1_CD 2_CD 3_CD
        4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. SLC_NNP /_NN CCL_NNP 21_CD recruits_VBZ both_DT naïve_NN lymphocytes_NNS and_CC
        antigen_NN stimulated_VBN DC_NNP into_IN T_NN cell_NN zones_NNS of_IN secondary_JJ
        lymphoid_NN organs_NNS ,_, co-localizing_JJ these_DT early_JJ immune_JJ response_NN
        constituents_NNS that_WDT culminate_NN in_IN cognate_NN T_NN cell_NN activation_NN [_NN
        1_CD ]_NN ._. The_DT capacity_NN to_TO facilitate_VB the_DT co-localization_JJ of_IN
        both_DT DC_NNP and_CC T_NN cells_NNS forms_VBZ a_DT strong_JJ rationale_NN for_IN the_DT use_NN of_IN
        SLC_NNP /_NN CCL_NNP 21_CD in_IN cancer_NN therapy_NN ._. In_IN previous_JJ studies_NNS we_PRP have_VBP
        shown_VBN that_IN the_DT SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ responses_NNS are_VBP
        accompanied_VBN by_IN the_DT enhanced_JJ elaboration_NN of_IN IFNγ_NNP ,_,
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ,_, MIG_NNP /_NN CXCL_NNP 9_CD ,_, GM-CSF_NNP and_CC IL-_NNP 12_CD ,_, but_CC decreased_VBD
        PGE_NNP 
        2_CD ,_, VEGF_NNP ,_, IL-_NNP 10_CD ,_, and_CC TGF-β_NNP at_IN the_DT tumor_NN
        site_NN [_NN 9_CD 10_CD ]_NN ._. In_IN addition_NN ,_, there_EX was_VBD a_DT marked_VBN increase_NN in_IN
        CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN cells_NNS secreting_VBG IFNγ_NNP and_CC GM-CSF_NNP as_RB well_RB as_IN DC_NNP
        expressing_VBG CD_NNP 11_CD c_SYM infiltrating_VBG the_DT tumors_NNS ._. MIG_NNP /_NN CXCL_NNP 9_CD and_CC
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP glutamine-leucine-arginine_JJ (_( ELR_NNP )_) -_: negative_JJ
        CXC_NNP chemokines_NNS that_WDT are_VBP potent_JJ chemoattractants_NNS for_IN
        activated_VBN T_NN cells_NNS [_NN 11_CD 12_CD 13_CD ]_NN ._. These_DT chemokines_NNS also_RB have_VBP
        in_IN common_JJ the_DT ability_NN to_TO signal_VB through_IN a_DT G_NNP protein-coupled_JJ
        receptor_NN ,_, CXCR_NNP 3_CD ,_, expressed_VBD on_IN activated_VBN T_NN lymphocytes_NNS ._.
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ,_, MIG_NNP /_NN CXCL_NNP 9_CD and_CC IFNγ_NNP are_VBP known_VBN to_TO have_VB potent_JJ
        anti-tumor_JJ activities_NNS 
        in_IN vivo_NN [_NN 14_CD 15_CD 16_CD 17_CD ]_NN ._. Both_DT
        MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP important_JJ for_IN the_DT anti-tumor_JJ
        activity_NN mediated_JJ by_IN IFNγ_NNP inducing_VBG cytokines_NNS such_JJ as_IN IL-_NNP 12_CD
        [_NN 16_CD 18_CD 19_CD ]_NN ._. Based_VBN on_IN these_DT findings_NNS we_PRP hypothesized_VBN that_DT
        augmentation_NN in_IN IFNγ_NNP ,_, MIG_NNP /_NN CXCL_NNP 9_CD ,_, and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD would_MD
        play_VB an_DT important_JJ role_NN in_IN the_DT SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ
        response_NN ._. Here_RB we_PRP show_VBP that_IN the_DT cytokines_NNS IFNγ_NNP ,_,
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC MIG_NNP /_NN CXCL_NNP 9_CD serve_VB as_IN effector_NN molecules_NNS in_IN
        SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ responses_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        Host_NN antigen_NN presenting_VBG cells_NNS (_( APC_NNP )_) are_VBP critical_JJ for_IN the_DT
        cross-presentation_JJ of_IN tumor_NN antigens_NNS [_NN 20_CD ]_NN ._. However_RB
        tumors_NNS have_VBP the_DT capacity_NN to_TO limit_VB APC_NNP maturation_NN ,_, function_NN
        and_CC infiltration_NN of_IN the_DT tumor_NN site_NN [_NN 21_CD 22_CD 23_CD 24_CD ]_NN ._. Thus_RB
        molecules_NNS that_WDT attract_VBP host_NN APC_NNP and_CC T_NN cells_NNS could_MD serve_VB as_IN
        potent_JJ agents_NNS for_IN cancer_NN immunotherapy_NN ._. A_DT potentially_RB
        effective_JJ pathway_NN to_TO restore_VB Ag_NNP presentation_NN is_VBZ the_DT
        establishment_NN of_IN a_DT chemotactic_JJ gradient_NN that_WDT favors_VBZ
        localization_NN of_IN both_DT activated_VBN DC_NNP and_CC Type_NNP 1_CD cytokine_NN
        producing_VBG lymphocytes_NNS at_IN the_DT tumor_NN site_NN ._. SLC_NNP /_NN CCL_NNP 21_CD ,_, a_DT CC_NNP
        chemokine_NN expressed_VBD in_IN high_JJ endothelial_NN venules_NNS and_CC in_IN T_NN
        cell_NN zones_NNS of_IN spleen_NN and_CC lymph_NN nodes_NNS ,_, strongly_RB attracts_VBZ
        naive_JJ T_NN cells_NNS and_CC DCs_NNP [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. Because_IN DCs_NNP are_VBP
        potent_JJ APCs_NNP that_DT function_NN as_IN principal_JJ activators_NNS of_IN T_NN
        cells_NNS ,_, the_DT capacity_NN to_TO facilitate_VB the_DT co-localization_JJ of_IN
        both_DT DC_NNP and_CC T_NN cells_NNS may_MD reverse_VB tumor-mediated_JJ immune_JJ
        suppression_NN and_CC orchestrate_NN effective_JJ cell-mediated_JJ immune_JJ
        responses_NNS [_NN 9_CD 10_CD 25_CD 26_CD 27_CD ]_NN ._. In_IN addition_NN to_TO its_PRP$
        immunotherapeutic_JJ potential_NN ,_, SLC_NNP /_NN CCL_NNP 21_CD has_VBZ been_VBN found_VBN to_TO
        have_VB potent_JJ angiostatic_JJ effects_NNS [_NN 28_CD ]_NN ,_, thus_RB adding_VBG
        further_JJ support_NN for_IN its_PRP$ use_NN in_IN cancer_NN therapy_NN ._. Based_VBN on_IN
        these_DT dual_JJ capacities_NNS ,_, we_PRP as_RB well_RB as_IN others_NNS have_VBP begun_VBN
        pre-clinical_JJ evaluation_NN of_IN SLC_NNP /_NN CCL_NNP 21_CD in_IN several_JJ tumor_NN
        models_NNS [_NN 9_CD 10_CD 25_CD 26_CD 27_CD ]_NN ._.
        Utilizing_NNP two_CD transplantable_JJ murine_NN lung_NN cancer_NN models_NNS ,_,
        we_PRP have_VBP previously_RB shown_VBN that_IN the_DT anti-tumor_JJ efficacy_NN of_IN
        SLC_NNP /_NN CCL_NNP 21_CD is_VBZ T_NN cell-dependent_JJ [_NN 9_CD ]_NN ._. In_IN both_DT models_NNS
        recombinant_JJ SLC_NNP /_NN CCL_NNP 21_CD administered_VBN intratumorally_RB led_VBN to_TO
        complete_VB tumor_NN eradication_NN in_IN 40_CD %_NN of_IN the_DT treated_VBN mice_NNS ._.
        Studies_NNS performed_VBD in_IN CD_NNP 4_CD and_CC CD_NNP 8_CD knockout_NN mice_NNS also_RB
        revealed_VBD a_DT requirement_NN for_IN both_DT CD_NNP 4_CD and_CC CD_NNP 8_CD lymphocytes_NNS
        subsets_NNS for_IN SLC_NNP /_NN CCL_NNP 21_CD mediated_JJ tumor_NN regression_NN ._. Consistent_NNP
        with_IN these_DT findings_NNS we_PRP found_VBD that_IN SLC_NNP therapy_NN did_VBD not_RB alter_VB
        tumor_NN growth_NN in_IN SCID_NNP mice_NNS ._. In_IN immune_JJ competent_JJ mice_NNS ,_,
        intratumoral_NN injection_NN of_IN SLC_NNP /_NN CCL_NNP 21_CD led_VBN to_TO a_DT significant_JJ
        increase_NN in_IN CD_NNP 4_CD and_CC CD_NNP 8_CD T_NN lymphocytes_NNS as_RB well_RB as_IN DC_NNP
        infiltrating_VBG the_DT tumor_NN and_CC the_DT draining_VBG lymph_NN nodes_NNS ._. The_DT
        cellular_JJ infiltrates_NNS were_VBD accompanied_VBN by_IN an_DT enhanced_JJ
        elaboration_NN of_IN IL-_NNP 12_CD ,_, IFNγ_NNP ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC MIG_NNP /_NN CXCL_NNP 9_CD at_IN
        the_DT tumor_NN site_NN [_NN 9_CD ]_NN ._.
        SLC_NNP /_NN CCL_NNP 21_CD is_VBZ documented_VBN to_TO have_VB direct_JJ anti-angiogenic_JJ
        effects_NNS [_NN 28_CD 29_CD ]_NN ;_: the_DT tumor_NN reductions_NNS observed_VBD in_IN this_DT
        model_NN could_MD have_VB been_VBN due_JJ to_TO participation_NN by_IN T_NN cells_NNS
        secreting_VBG IFNγ_NNP leading_VBG to_TO inhibition_NN of_IN angiogenesis_NNS via_IN
        MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ,_, as_RB well_RB as_IN T_NN cell-dependent_JJ
        immunity_NN [_NN 16_CD ]_NN ._. IFNγ_NNP mediates_NNS a_DT range_NN of_IN biological_JJ
        effects_NNS that_WDT facilitate_VBP anticancer_NN immunity_NN ._. MIG_NNP /_NN CXCL_NNP 9_CD and_CC
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP potent_JJ angiostatic_JJ factors_NNS that_WDT are_VBP
        induced_VBN by_IN IFNγ_NNP [_NN 14_CD 16_CD 17_CD ]_NN ._. Both_DT MIG_NNP /_NN CXCL_NNP 9_CD and_CC
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP chemotactic_JJ for_IN stimulated_VBN
        CXCR_NNP 3_CD -_: expressing_VBG activated_VBN T_NN lymphocytes_NNS that_WDT could_MD further_RB
        amplify_VB IFNγ_NNP at_IN the_DT tumor_NN site_NN [_NN 30_CD ]_NN ._. Hence_RB we_PRP postulated_JJ
        that_IN in_IN addition_NN to_TO IFNγ_NNP ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC MIG_NNP /_NN CXCL_NNP 9_CD would_MD
        also_RB be_VB important_JJ contributors_NNS to_TO the_DT tumor_NN reduction_NN in_IN
        the_DT context_NN of_IN SLC_NNP /_NN CCL_NNP 21_CD therapy_NN ._.
        To_TO determine_VB the_DT importance_NN of_IN MIG_NNP /_NN CXCL_NNP 9_CD ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD
        and_CC IFNγ_NNP in_IN the_DT SLC_NNP /_NN CCL_NNP 21_CD mediated_JJ antitumor_NN response_NN ,_,
        these_DT cytokines_NNS were_VBD depleted_VBN in_IN SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS ._.
        Anti-_NNP IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ,_, MIG_NNP /_NN CXCL_NNP 9_CD and_CC IFNγ_NNP antibodies_NNS each_DT
        partially_RB but_CC yet_RB significantly_RB inhibited_VBD the_DT anti-tumor_JJ
        efficacy_NN of_IN SLC_NNP /_NN CCL_NNP 21_CD (_( Figure_NN 1_CD *_NN p_NN <_NN 0_CD ._. 01_CD compared_VBN to_TO
        the_DT control_NN antibody_NN group_NN )_) ._. Neutralization_NNP of_IN IFNγ_NNP caused_VBD
        a_DT significant_JJ decrease_NN in_IN both_DT MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD
        indicating_VBG that_IN these_DT chemokines_NNS are_VBP largely_RB IFNγ_NNP
        dependent_JJ ._. Thus_RB ,_, an_DT increase_NN in_IN IFNγ_NNP at_IN the_DT tumor_NN site_NN of_IN
        SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS could_MD explain_VB the_DT relative_JJ increases_NNS
        in_IN IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC MIG_NNP /_NN CXCL_NNP 9_CD ._. The_DT converse_NN was_VBD also_RB
        observed_VBN ;_: IFNγ_NNP production_NN at_IN the_DT tumor_NN site_NN was_VBD found_VBN to_TO be_VB
        MIG_NNP /_NN CXCL_NNP 9_CD -_: and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD -_: dependent_JJ as_IN indicated_VBN by_IN the_DT
        fact_NN that_DT neutralization_NN of_IN these_DT cytokines_NNS caused_VBD a_DT
        significant_JJ decrease_NN in_IN IFNγ_NNP (_( Figure_NN 2_LS )_) ._. Neutralization_NNP of_IN
        any_DT one_CD of_IN these_DT cytokines_NNS caused_VBD a_DT concomitant_NN decrease_NN in_IN
        all_DT three_CD cytokines_NNS ,_, thus_RB indicating_VBG that_IN IFNγ_NNP ,_, MIG_NNP /_NN CXCL_NNP 9_CD
        and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP interdependent_NN in_IN the_DT
        SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ responses_NNS ._. Based_VBN on_IN these_DT
        findings_NNS ,_, we_PRP speculated_VBD that_IN the_DT decrease_NN of_IN IP-_NNP 10_CD /_NN CXCL_NNP 10_CD
        and_CC MIG_NNP /_NN CXCL_NNP 9_CD led_VBN to_TO a_DT decrease_NN in_IN IFNγ_NNP by_IN limiting_VBG the_DT
        influx_NN of_IN T_NN cells_NNS producing_VBG IFNγ_NNP at_IN the_DT tumor_NN site_NN ._. Because_IN
        MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD are_VBP chemotactic_JJ for_IN stimulated_VBN
        CXCR_NNP 3_CD expressing_VBG activated_VBN T_NN lymphocytes_NNS ,_, we_PRP determined_VBD if_IN
        neutralizing_VBG these_DT chemokines_NNS 
        in_IN vivo_NN in_IN the_DT SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS
        would_MD decrease_VB the_DT frequency_NN of_IN CXCR_NNP 3_CD expressing_VBG T_NN cells_NNS at_IN
        the_DT tumor_NN sites_NNS ._. Compared_VBN to_TO SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS
        receiving_VBG control_NN antibody_NN ,_, flow_NN cytometric_JJ evaluation_NN of_IN
        single-cell_JJ suspensions_NNS of_IN non-necrotic_JJ tumors_NNS from_IN
        SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS receiving_VBG neutralizing_VBG antibodies_NNS to_TO
        MIG_NNP /_NN CXCL_NNP 9_CD ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC IFNγ_NNP showed_VBD 10_CD ,_, 12_CD and_CC 31_CD %_NN
        decreases_NNS ,_, respectively_RB ,_, in_IN the_DT gated_JJ CD_NNP 3_CD CXCR_NNP 3_CD +_NN veT_NN cell_NN
        populations_NNS (_( Table_NNP 1_LS )_) ._. The_DT fact_NN that_DT neutralization_NN of_IN IFNγ_NNP

        was_VBD the_DT most_RBS efficient_JJ at_IN decreasing_VBG the_DT total_JJ number_NN of_IN
        CXCR_NNP 3_CD -_: activated_VBN T_NN cells_NNS may_MD be_VB due_JJ to_TO the_DT decrease_NN in_IN the_DT
        IFNγ-dependent_NNP CXCR_NNP 3_CD ligands_NNS MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ._.
        Individually_NNP ,_, neutralizing_VBG MIG_NNP /_NN CXCL_NNP 9_CD and_CC /_NN or_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD
        only_RB led_VBN to_TO a_DT partial_JJ decrease_NN in_IN the_DT total_JJ number_NN of_IN
        CXCR_NNP 3_CD -_: activated_VBN T_NN cells_NNS ._. Because_IN MIG_NNP /_NN CXCL_NNP 9_CD and_CC IP-_NNP 10_CD /_NN CXCL_NNP 10_CD
        share_NN the_DT same_JJ receptor_NN (_( CXCR_NNP 3_LS )_) ,_, one_CD possible_JJ explanation_NN
        of_IN a_DT partial_JJ decrease_NN in_IN CXCR_NNP 3_CD -_: activated_VBN T_NN cells_NNS is_VBZ that_DT
        neutralization_NN of_IN one_CD ligand_NN may_MD overexpose_NN the_DT receptor_NN to_TO
        the_DT other_JJ ligand_NN ._. Furthermore_RB ,_, because_IN murine_NN SLC_NNP /_NN CCL_NNP 21_CD
        binds_NNS CXCR_NNP 3_CD receptor_NN ,_, SLC_NNP /_NN CCL_NNP 21_CD may_MD be_VB recruiting_VBG CXCR_NNP 3_CD
        +_NN veT_NN cells_NNS directly_RB ._. An_DT alternative_JJ explanation_NN is_VBZ that_IN
        residual_JJ cytokines_NNS such_JJ as_IN IFN-inducible_NNP T_NN cell_NN α_NN
        chemoattractant_NN (_( ITAC_NNP /_NN CXCL_NNP 11_CD )_) present_JJ after_IN 
        in_IN vivo_NN neutralization_NN of_IN IFNγ_NNP ,_, MIG_NNP ,_,
        IP-_NNP 10_CD may_MD have_VB remaining_VBG activity_NN and_CC attract_VB CXCR_NNP 3_CD +_NN veT_NN
        cells_NNS ._. Our_PRP$ results_NNS imply_VBP that_IN all_DT 3_CD cytokines_NNS ,_, IFNγ_NNP ,_, MIG_NNP
        and_CC IP-_NNP 10_CD play_VB interrelated_JJ roles_NNS in_IN the_DT recruitment_NN of_IN
        CXCR_NNP 3_CD -_: activated_VBN T_NN cells_NNS in_IN SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ
        responses_NNS ._. While_IN the_DT number_NN of_IN CD_NNP 4_CD and_CC CD_NNP 8_CD cells_NNS remained_VBD
        unaltered_JJ ,_, compared_VBN to_TO SLC_NNP /_NN CCL_NNP 21_CD -_: treated_VBN mice_NNS receiving_VBG
        control_NN antibody_NN ,_, mice_NNS administered_VBN neutralizing_VBG antibodies_NNS
        to_TO MIG_NNP /_NN CXCL_NNP 9_CD ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC IFNγ_NNP showed_VBD respective_JJ
        decreases_NNS of_IN 38_CD ,_, 28_CD and_CC 16_CD %_NN in_IN the_DT number_NN of_IN CD_NNP 11_CD c_SYM +_NN DEC_NNP 205_CD
        +_NN DC_NNP infiltrating_VBG the_DT tumor_NN (_( Table_NNP 1_LS )_) ._. At_IN present_JJ it_PRP is_VBZ not_RB
        clear_JJ why_WRB there_EX is_VBZ a_DT decrease_NN in_IN DC_NNP following_VBG
        neutralization_NN of_IN MIG_NNP /_NN CXCL_NNP 9_CD ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC IFNγ_NNP ._. A_DT
        plausible_JJ explanation_NN is_VBZ that_IN these_DT cytokines_NNS may_MD be_VB
        involved_VBN in_IN complex_JJ interactions_NNS with_IN other_JJ molecules_NNS that_WDT
        are_VBP chemotactic_JJ for_IN DC_NNP ._. Further_RB studies_VBZ are_VBP required_VBN to_TO
        delineate_NN the_DT mechanisms_NNS responsible_JJ for_IN MIG_NNP /_NN CXCL_NNP 9_CD ,_,
        IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC IFNγ_NNP mediated_JJ localization_NN of_IN DC_NNP at_IN the_DT
        tumor_NN site_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ results_NNS suggest_VBP that_IN the_DT anti-tumor_JJ properties_NNS of_IN
        SLC_NNP /_NN CCL_NNP 21_CD may_MD be_VB due_JJ to_TO its_PRP$ chemotactic_JJ capacity_NN in_IN
        co-localization_JJ of_IN DC_NNP and_CC T_NN cells_NNS as_RB well_RB as_IN in_IN part_NN to_TO the_DT
        induction_NN of_IN key_JJ cytokines_NNS such_JJ as_IN IFNγ_NNP ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC
        MIG_NNP /_NN CXCL_NNP 9_CD ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Reagents_NNP
          Abs_NNP to_TO murine_NN IFNγ_NNP ,_, recombinant_JJ IFNγ_NNP were_VBD obtained_VBN
          from_IN PharMingen_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. Abs_NNP to_TO murine_NN MIG_NNP /_NN CXCL_NNP 9_CD ,_,
          IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC recombinant_JJ cytokine_NN standards_NNS was_VBD
          purchased_VBN from_IN R_NN &_CC D_NNP (_( Minneapolis_NNP ,_, MN_NNP )_) ._. Recombinant_NNP
          SLC_NNP /_NN CCL_NNP 21_CD was_VBD obtained_VBN from_IN PeproTech_NNP ._. (_( Rocky_NNP Hill_NNP ,_, NJ_NNP )_) ._.
          Polyclonal_NNP goat_NN anti-murine_JJ MIG_NNP /_NN CXCL_NNP 9_CD and_CC anti-murine_JJ
          IP-_NNP 10_CD /_NN CXCL_NNP 10_CD specific_JJ anti-serum_JJ were_VBD produced_VBN and_CC
          characterized_VBN as_RB previously_RB described_VBD [_NN 31_CD ]_NN ._. Anti-mouse_NNP
          IFNγ_NNP monoclonal_NN (_( R_NN 4_CD -_: 462_CD ,_, American_NNP Type_NNP Culture_NNP
          Collection_NNP ,_, Rockville_NNP ,_, Maryland_NNP ,_, MD_NNP )_) neutralizing_VBG
          antibody_NN was_VBD purified_JJ by_IN affinity_NN chromatography_NN from_IN
          SCID_NNP mice_NNS ascites_NNS ,_, which_WDT was_VBD generated_VBN 3_CD -_: 4_CD weeks_NNS after_IN
          intraperitoneal_NN injection_NN of_IN 10_CD 6_CD R_NN 4_CD -_: 462_CD hybridoma_NN cells_NNS
          per_IN mouse_NN [_NN 32_CD ]_NN ._. For_IN flow_NN cytometry_NN ,_, labeled_VBN antibodies_NNS
          (_( FITC_NNP ,_, PE_NNP ,_, PerCP_NNP )_) against_IN the_DT T_NN cell_NN surface_NN markers_NNS to_TO
          CD_NNP 3_CD ,_, CD_NNP 4_CD ,_, CD_NNP 8_CD and_CC against_IN the_DT DC_NNP markers_NNS ,_, CD_NNP 11_CD c_SYM and_CC DEC_NNP
          205_CD and_CC the_DT appropriate_JJ controls_NNS were_VBD purchased_VBN from_IN
          PharMingen_NNP ._. FITC_NNP labeled_VBD anti-rabbit_JJ IgG_NNP was_VBD purchased_VBN
          from_IN PharMingen_NNP ._. Rabbit_NNP anti-mouse_JJ CXCR_NNP 3_CD antibody_NN was_VBD
          purchased_VBN from_IN Zymed_NNP Laboratories_NNPS Inc_NNP ._. (_( So_RB ._. San_NNP
          Francisco_NNP ,_, CA_NNP )_) ._. Murine_NNP serum_NN albumin_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) was_VBD utilized_JJ as_IN control_NN injections_NNS for_IN SLC_NNP /_NN CCL_NNP 21_CD ._.
        
        
          Cell_NNP culture_NN and_CC tumorigenesis_NNS model_NN
          A_DT weakly_RB immunogenic_JJ lung_NN cancer_NN ,_, Lewis_NNP lung_NN carcinoma_NN
          (_( 3_CD LL_NNP ,_, H-_NNP 2_CD b_SYM )_) obtained_VBN from_IN ATCC_NNP (_( CRL-_NNP 1642_CD ,_, LLC_NNP )_) was_VBD
          utilized_JJ for_IN assessment_NN of_IN cytokines_NNS important_JJ for_IN
          SLC_NNP /_NN CCL_NNP 21_CD -_: mediated_JJ anti-tumor_JJ responses_NNS 
          in_IN vivo_NN ._. The_DT cells_NNS were_VBD routinely_RB
          cultured_JJ as_IN monolayers_NNS in_IN 25_CD cm_NN 3_CD tissue_NN culture_NN flasks_NNS
          containing_VBG RPMI_NNP 1640_CD medium_NN (_( Irvine_NNP Scientific_NNP ,_, Santa_NNP
          Anna_NNP ,_, CA_NNP )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_)
          (_( Gemini_NNP Bioproducts_NNP ,_, Calabasas_NNP ,_, CA_NNP )_) ,_, penicillin_NN (_( 100_CD
          U_NNP /_NN ml_NN )_) ,_, streptomycin_NN (_( 0_CD ._. 1_LS mg_NN /_NN ml_NN )_) ,_, 2_CD mM_NN glutamine_NN (_( JRH_NNP
          Biosciences_NNP ,_, Lenexa_NNP ,_, KS_NNP )_) and_CC maintained_VBN at_IN 37_CD °_NN C_NNP in_IN a_DT
          humidified_JJ atmosphere_NN containing_VBG 5_CD %_NN CO_NNP 
          2_CD in_IN air_NN ._. The_DT cell_NN lines_NNS were_VBD
          mycoplasma_NN free_JJ and_CC cells_NNS were_VBD utilized_JJ up_IN to_TO the_DT tenth_NN
          passage_NN before_IN thawing_VBG frozen_VBN stock_NN cells_NNS from_IN liquid_JJ N_NNP 
          2_CD ._.
          For_IN tumorigenesis_NNS experiments_NNS ,_, 10_CD 53_CD LL_NNP tumor_NN cells_NNS
          were_VBD inoculated_JJ by_IN s_VBZ ._. c_SYM ._. injection_NN in_IN the_DT right_JJ supra_NN
          scapular_NN area_NN of_IN C_NNP 57_CD Bl_NNP /_NN 6_CD mice_NNS and_CC tumor_NN volumes_NNS were_VBD
          monitored_VBN three_CD times_NNS each_DT week_NN ._. Five_CD day_NN established_VBD
          tumors_NNS were_VBD treated_VBN with_IN intratumoral_NN injection_NN of_IN 0_CD ._. 5_CD μg_NN
          of_IN recombinant_JJ murine_NN SLC_NNP /_NN CCL_NNP 21_CD (_( Pepro_NNP Tech_NNP ,_, Rocky_NNP Hill_NNP ,_,
          NJ_NNP )_) or_CC murine_NN serum_NN albumin_NN (_( utilized_JJ as_IN an_DT irrelevant_JJ
          protein_NN for_IN control_NN injections_NNS )_) were_VBD administered_VBN three_CD
          times_NNS per_IN week_NN for_IN two_CD weeks_NNS as_RB previously_RB described_VBD [_NN 9_CD
          ]_NN ._. 24_CD h_NN prior_RB to_TO SLC_NNP /_NN CCL_NNP 21_CD treatment_NN ,_, and_CC then_RB three_CD
          times_NNS a_DT week_NN ,_, mice_NNS were_VBD injected_VBN i_NNP ._. p_NN ._. with_IN 1_CD ml_NN /_NN dose_NN of_IN
          anti-_NN IP-_NNP 10_CD /_NN CXCL_NNP 10_CD ,_, or_CC anti-_NN MIG_NNP /_NN CXCL_NNP 9_CD ,_, or_CC 100_CD μg_NN /_NN dose_NN of_IN
          purified_JJ monoclonal_NN anti-_NN IFNγ_NNP or_CC appropriate_JJ control_NN
          antibodies_NNS (_( goat_NN IgG_NNP and_CC rat_NN IgG_NNP )_) at_IN equivalent_NN doses_NNS for_IN
          the_DT duration_NN of_IN the_DT experiment_NN ._. In_IN response_NN to_TO these_DT
          antibodies_NNS ,_, there_EX was_VBD a_DT significant_JJ reduction_NN of_IN the_DT
          respective_JJ cytokines_NNS 
          in_IN vivo_NN (_( Figure_NN 2_LS )_) ._. Tumor_NNP volume_NN
          was_VBD calculated_VBN as_RB previously_RB described_VBD [_NN 9_CD ]_NN ._.
        
        
          Cytokine_NNP ELISA_NNP
          MIG_NNP /_NN CXCL_NNP 9_CD ,_, IP-_NNP 10_CD /_NN CXCL_NNP 10_CD and_CC IFNγ_NNP were_VBD quantified_VBN using_VBG
          a_DT modification_NN of_IN a_DT double_JJ ligand_NN method_NN as_RB previously_RB
          described_VBD [_NN 33_CD ]_NN ._.
        
        
          Flow_NNP Cytometry_NNP
          Flow_NNP cytometric_JJ analyses_NNS for_IN T_NN cell_NN and_CC DC_NNP markers_NNS
          were_VBD performed_VBN on_IN a_DT FACScan_NNP flow_NN cytometer_NN (_( Becton_NNP
          Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP )_) in_IN the_DT University_NNP of_IN California_NNP ,_,
          Los_NNP Angeles_NNP ,_, Jonsson_NNP Cancer_NNP Center_NNP Flow_NNP Cytometry_NNP Core_NNP
          Facility_NNP ._. Cells_NNP were_VBD identified_VBN as_IN lymphocytes_NNS or_CC DC_NNP by_IN
          gating_VBG based_VBN on_IN forward_RB and_CC side_NN scatter_NN profiles_NNS ._. CD_NNP 11_CD c_SYM
          +_NN veDCs_NNS were_VBD defined_VBN as_IN the_DT bright_JJ populations_NNS within_IN
          tumor_NN nodules_NNS ._. 10_CD ,_, 000_CD -_: gated_JJ events_NNS were_VBD collected_VBN and_CC
          analyzed_VBN using_VBG Cell_NNP Quest_NNP software_NN (_( Becton_NNP Dickinson_NNP )_) ._.
          For_IN staining_VBG ,_, two_CD or_CC three_CD fluorochromes_NNS (_( PE_NNP ,_, FITC_NNP ,_,
          PerCP_NNP )_) (_( PharMingen_NNP )_) were_VBD used_VBN to_TO gate_NN on_IN the_DT CD_NNP 3_CD ,_, CD_NNP 4_CD and_CC
          CD_NNP 8_CD T_NN lymphocyte_NN population_NN or_CC CD_NNP 11_CD c_SYM +_NN veDC_NN in_IN single_JJ cell_NN
          suspensions_NNS from_IN tumor_NN nodule_NN ._. For_IN CXCR_NNP 3_CD expression_NN ,_, T_NN
          cells_NNS were_VBD doubly_RB stained_JJ for_IN CD_NNP 3_CD and_CC CXCR_NNP 3_CD cell_NN surface_NN
          markers_NNS ._.
        
        
          Statistical_NNP Analysis_NNP
          Groups_NNS of_IN 8_CD mice_NNS were_VBD used_VBN ._. Statistical_NNP analyses_NNS of_IN
          the_DT data_NNS in_IN figures_NNS 1_CD ,_, 2_CD and_CC in_IN table_NN 1_CD were_VBD performed_VBN
          using_VBG the_DT paired_VBN Student_NNP t_NN test_NN ._.
        
      
      
        Author_NN 's_POS contributions_NNS
        Author_NN 1_CD SS_NNP and_CC Author_NN 2_CD SCY_NNP coordinated_VBN and_CC carried_VBN out_RP
        all_PDT the_DT experiments_NNS ._. Authors_NNP SH_NNP ,_, LXZ_NNP ,_, MH_NNP ,_, RKB_NNP and_CC MDB_NNP
        contributed_VBD to_TO the_DT discussion_NN of_IN the_DT article_NN ._. Author_NN JFL_NNP
        together_RB with_IN SS_NNP performed_VBD the_DT statistical_JJ analyses_NNS ._.
        Authors_NNP RMS_NNP and_CC SMD_NNP together_RB with_IN SS_NNP conceived_VBD of_IN the_DT
        study_NN ,_, participated_VBD in_IN its_PRP$ design_NN and_CC drafted_VBD the_DT
        manuscript_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN
      
    
  
